Catherine E. Arney (Cassie)

Cassie Arney's practice focuses on the executive compensation and employee benefits aspects of corporate acquisitions, dispositions, and mergers.

Cassie has extensive experience in working with and crafting complex profits interest programs and partnership waterfall provisions. She frequently advises clients on the restructuring of their equity incentive programs and on various alternative incentive mechanisms, such as phantom equity and bonus programs. Cassie assists regularly with analyses relating to tax implications of golden parachute payments (Section 280G of the Internal Revenue Code) in private and public company transactions as well. Cassie also has experience drafting and negotiating employment and severance agreements and advising clients regarding the administration and compliance of employee benefit plans, programs, and arrangements with the Internal Revenue Code and the Employee Retirement Income Security Act (ERISA).

In addition to a number of private equity acquisitions and dispositions, some of the transactions on which Cassie has advised include Diebold Nixdorf's restructuring of more than $2.7 billion in funded debt; Astellas Pharma's acquisition of Iveric bio, Inc. for $5.9 billion; the $1.3 billion sale of Calgon Carbon to Kuraray; TDK Corporation's $1.3 billion acquisition of InvenSense; and the $1.5 billion sale of RTI International Metals to Alcoa.